Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update
by Renee Jackson · The Cerbat GemAprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totaling 109,910 shares, a drop of 82.8% from the March 31st total of 640,347 shares. Currently, 1.1% of the shares of the stock are sold short. Based on an average trading volume of 410,244 shares, the short-interest ratio is presently 0.3 days.
Analysts Set New Price Targets
A number of brokerages recently issued reports on APRE. Zacks Research upgraded shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Monday. Wedbush reiterated an “outperform” rating and set a $7.00 target price on shares of Aprea Therapeutics in a research report on Tuesday, March 31st. Finally, HC Wainwright dropped their target price on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.10.
View Our Latest Stock Analysis on APRE
Aprea Therapeutics Trading Up 5.2%
Shares of Aprea Therapeutics stock traded up $0.05 during mid-day trading on Friday, reaching $0.93. 40,651 shares of the stock were exchanged, compared to its average volume of 852,530. The company has a market cap of $11.14 million, a price-to-earnings ratio of -0.47 and a beta of 1.47. Aprea Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $2.22. The firm has a 50-day simple moving average of $0.80 and a 200 day simple moving average of $0.97.
Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.06. The firm had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 96.33%. On average, research analysts predict that Aprea Therapeutics will post -0.82 EPS for the current fiscal year.
Institutional Investors Weigh In On Aprea Therapeutics
An institutional investor recently bought a new position in Aprea Therapeutics stock. DRW Securities LLC purchased a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned 1.73% of Aprea Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.19% of the company’s stock.
Aprea Therapeutics Company Profile
Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.
Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.